Prediction of outcome in cancer patients with febrile neutropenia: Comparison of the multinational association of supportive care in cancer risk-index score with procalcitonin, C-reactive protein, serum amyloid A, and interleukins-1β, -6, -8 and -10

European Journal of Cancer Care

Volumn 16, Issue 6, 2007, Pages 475-483

  Uys, A ^a   Rapoport, B L ^a   Fickl, H ^b   Meyer, P W A ^b   Anderson, R ^b  

^a Medical Oncology Centre of Rosebank   (South Africa)

^b UNIVERSITY OF PRETORIA   (South Africa)

Author keywords

Acute phase reactants; Cancer; Cytokines; Febrile neutropenia; Infection; MASCC score; Procalcitonin

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALCITONIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; INTERLEUKIN DERIVATIVE; PROCALCITONIN; PROTEIN PRECURSOR; SERUM AMYLOID A;

ADOLESCENT; ADULT; AGED; ARTICLE; BACTERIAL INFECTION; BLOOD; CASE CONTROL STUDY; COMPARATIVE STUDY; FEMALE; FEVER; HUMAN; IMMUNOLOGY; MALE; MIDDLE AGED; NEOPLASM; NEUTROPENIA; PREDICTION AND FORECASTING; PROGNOSIS; STATISTICAL MODEL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; BACTERIAL INFECTIONS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CALCITONIN; CASE-CONTROL STUDIES; FEMALE; FEVER; HUMANS; INTERLEUKIN-10; INTERLEUKIN-1BETA; INTERLEUKIN-6; INTERLEUKIN-8; INTERLEUKINS; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEIN PRECURSORS; SERUM AMYLOID A PROTEIN; TREATMENT OUTCOME;

EID: 35348978703     PISSN: 09615423     EISSN: 13652354     Source Type: Journal    
DOI: 10.1111/j.1365-2354.2007.00780.x     Document Type: Article

References (36)

1. Abrahamsson J., Påhlman M. Mellander L. (1997) Interleukin 6, but not tumour necrosis factor-α, is a good predictor of severe infection in febrile neutropenic and non-neutropenic children with malignancy. Acta Paediatrica 86, 1059 1964.
2. Bernard L., Ferrière F., Casassus P., Malas F., Leveque S., Guillevin L. Lortholary O. (1998) Procalcitonin as an early marker of bacterial infection in severely neutropenic febrile adults. Clinical Infectious Diseases 27, 914 915.
3. Boussekey N., Leroy O., Georges H., Devos P., d'Escrivan T. Guery B. (2005) Diagnostic and prognostic values of admission procalcitonin levels in community-acquired pneumonia in an intensive care unit. Infection 33, 257 263.
4. Chan Y.L., Tseng C.P., Tsay P.K., Chang S.S., Chiu T.F. Chen J.C. (2004) Procalcitonin as a marker of bacterial infection in the emergency department: an observational study. Critical Care 8, R12 R20.
5. Chirouze C., Schuhmacher H., Rabaud C., Gill H., Khayat N., Estavoyer J., May T. Hoen B. (2002) Low serum procalcitonin level accurately predicts the absence of bacteraemia in adult patients with acute fever. Clinical Infectious Diseases 15, 156 161.
6. De Bont E.S., Vellenga E., Swaanenburg J.C., Fidler V., Visser-van Brummen P.J. Kamps W.A. (1999) Plasma IL-8 and IL-6 levels can be used to define a group with low risk of septicaemia among cancer patients with fever and neutropenia. British Journal of Haematology 107, 375 380.
7. De Bont E.S.J.M., Vellenga E. Swaanenburg J. (2000) Procalcitonin: a diagnostic marker of bacterial infection in neutropenic cancer patients with fever. Infection 28, 398 400.
8. Engel A., Mack E., Kern P. Kern W.V. (1998) An analysis of interleukin-8, interleukin-6 and C-reactive protein serum concentrations to predict fever, Gram-negative bacteraemia and complicated infection in neutropenic cancer patients. Infection 26, 213 221.
9. Engel A., Steinbach G., Kern P. Kern W.V. (1999) Diagnostic value of procalcitonin serum levels in neutropenic patients with fever: comparison with interleukin-8. Scandinavian Journal of Infectious Diseases 31, 185 189.
10. Engervall P., Andersson B. Björkholm M. (1995a) Clinical significance of serum cytokine patterns during start of fever in patients with neutropenia. British Journal of Haematology 91, 838 845.
11. Engervall P., Granström M., Andersson B. Björkholm M. (1995b) Monitoring of endotoxin, interleukin-6 and C-reactive protein serum concentrations in neutropenic patients with fever. European Journal of Haematology 54, 226 234.
12. Feld R. (2000) Multinational cooperation in trials and guidelines dealing with febrile neutropenia. International Journal of Antimicrobial Agents 16, 185 187.
13. Ffmeaux T. Pugin T. (2002) Role of interleukin-10 in the intracellular sequestration of human leucocyte antigen-DR in monocytes during septic shock. American Journal of Respiratory and Critical Care Medicine 166, 1475 1483.
14. Fleischhack G., Kambeck I., Cipic D., Hasan C. Bode U. (2000) Procalcitonin in paediatric cancer patients: its diagnostic relevance is superior to that of C-reactive protein, interleukin 6, interleukin 8, soluble interleukin 2 receptor and soluble tumour necrosis factor receptor II. British Journal of Haematology 111, 1093 1102.
15. Giamarellou H., Giamarellos-Bourboulis E.J., Repoussis P., Galani L., Anagnostopoulos N., Grecka P., Lubos A., Aoun M., Athanassiou K., Bou E., Devigili E., Krcmery V., Menichetti F., Panaretou E., Papageorgiou E. Plachouras D. (2004) Potential use of procalcitonin as a diagnostic criterion in febrile neutropenia: experience from a multicentre study. Clinical Microbiology and Infection 10, 628 633.
16. Giamarellos-Bourboulis E.J., Grecka P., Poulakou G., Poulakou G., Anargyrou K., Katsilambros N. Giamarellou H. (2001) Assessment of procalcitonin as a diagnostic marker of underlying infection in patients with febrile neutropenia. Clinical Infectious Diseases 32, 1718 1725.
17. Gibot S., Cravoisy A., Levy B., Bene M., Faure G. Bollaert P. (2004) Soluble triggering receptor expressed on myeloid cells and the diagnosis of pneumonia. New England Journal of Medicine 350, 451 458.
18. Harbarth S., Holeckova K., Froidevaux C., Pittet D., Ricou B., Grau G.E., Vadas L., Pugin J. and the Geneva Sepsis Network (2001) Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. American Journal of Respiratory and Critical Care Medicine 164, 396 402.
19. Jimeno A., Garcia-Velasco A., del Val O., Gonzalez-Billalabeitia E., Hernando S., Hernandez R., Sanchez-Munoz A., Lopez-Martin A., Duran Robles L., Cortes-Funes H. Paz-Ares L. (2004) Assessment of procalcitonin as a diagnostic marker in patients with solid tumors and febrile neutropenia. Cancer 100, 2462 2469.
20. Karan M.A. (2002) Predictive value of higher plasma interleukin-6 levels in patients with febrile neutropenia. Archives of Medical Research 33, 557 561.
21. Kern W.V., Heiss M. Steinbach G. (2001) Prediction of Gram-negative bacteraemia in patients with cancer and febrile neutropenia by means of interleukin-8 levels in serum: targeting empirical monotherapy versus combination therapy. Clinical Infectious Diseases 32, 832 835.
22. Klastersky J., Paesmans M., Rubenstein E.B., Boyer M., Elting L., Feld R., Gallagher J., Herrstedt J., Rapoport B., Rolston K. Talcott J.A. (2000) The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. Journal of Clinical Oncology 18, 3038 3051.
23. Lehrnbecher T., Venzon D., de Haas M., Chanock S.J. Kuhl J. (1999) Assessment of measuring circulating levels of interleukin-6, interleukin-8, C-reactive protein, soluble Fcγ receptor type III, and mannose-binding protein in febrile children with cancer and neutropenia. Clinical Infectious Diseases 29, 414 419.
24. Liaudat S., Dayer E., Praz G., Bille J. Troillet N. (2001) Usefulness of procalcitonin serum level for the diagnosis of bacteraemia. European Journal of Clinical Microbiology and Infectious Diseases 20, 524 527.
25. Meisner M. (2005) Biomarkers of sepsis: clinically useful? Current Opinion in Critical Care 11, 473 480.
26. Penel N., Fournier C., Clisant S. N'Guyen M. (2004) Causes of fever and value of C-reactive protein and procalcitonin in differentiating infections from paraneoplastic fever. Support Care Cancer 12, 593 598.
27. Persson L., Engervall P., Magnuson A., Vikerfors T., Soderquist B., Hannson L.O. Tidefelt U. (2004) Use of inflammatory markers for early detection of bacteraemia in patients with febrile neutropenia. Scandinavian Journal of Infectious Diseases 36, 365 337.
28. Rackoff W.R., Gonin R., Robinson C. Kreissman S.G. (1996) Predicting the risk of bacteraemia in children with fever and neutropenia. Journal of Clinical Oncology 14, 919 924.
29. Ruokonen E., Nousiainen T., Pulkki K. Takala J. (1999) Procalcitonin concentrations in patients with neutropenic fever. European Journal of Clinical Microbiology and Infectious Disease 18, 283 285.
30. Sauer M., Tiede K., Volland R. Zintl F. (2000) Procalcitonin and C-reactive protein: comparison of two markers for sepsis syndrome in severely immunocompromised children after bone marrow transplantation. Clin Peadiatr 212, 10 15.
31. Schönbohn H., Schuler M., Kolbe K., Peschel C., Huber C., Bemb W. Aulitzky W.E. (1995) Plasma levels of IL-1, TNF alpha, IL-6, IL-8, G-CSF and IL1-RA during febrile neutropenia: results of a prospective study in patients undergoing chemotherapy for acute myelogenous leukemia. Annals of Hematology 71, 161 168.
32. Südhoff T., Giagounidis A. Karthaus M. (2000) Evaluation of neutropenic fever: value of serum and plasma parameters in clinical practice. Chemotherapy 46, 77 85.
33. Svaldi M., Hirber J., Lanthaler A.I., Mayr O., Faes S., Peer E. Mitterer M. (2001) Procalcitonin-reduced sensitivity and specificity in heavily leukopenic and immunosuppressed patients. British Journal of Haematology 115, 53 57.
34. Uys A., Rapoport B.L. Anderson R. (2004) Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer risk-index score. Supportive Care in Cancer 12, 555 560.
35. Viscoli C. Castagnola E. (2002) Treatment of febrile neutropenia: what is new? Current Opinion in Infectious Diseases 15, 377 382.
36. Von Lilienfeld-Toal M., Dietrich M.P., Glasmacher A., Lehman L., Breig P., Hahn C., Schmidt-Wolf I.G., Marklein G., Schroeder S. Stuber F. (2004) Markers of bacteraemia in febrile neutropenic patients with haematological malignancies: procalcitonin and IL-6 are more reliable than C-reactive protein. European Journal of Clinical Microbiology and Infectious Diseases 23, 539 544.